{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T14:41:10Z","timestamp":1783521670574,"version":"3.55.0"},"reference-count":49,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,1,6]],"date-time":"2023-01-06T00:00:00Z","timestamp":1672963200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Surg."],"abstract":"<jats:p>Diffuse malignant peritoneal mesothelioma (DMPM) is an unusual and life-threatening locally invasive tumor. The morbidity and mortality of the disease are associated with progressive local effects in the abdominal cavity, such as abdominal distention, painful sensations, and early saturation with reduced oral intake, which eventually lead to intestinal obstruction and cachexia. Computed tomography (CT) has been widely used as a first-line diagnostic tool for DMPM. In addition, the most sensitive immunohistochemical markers of DMPM include WT 1, D2-40, and calmodulin. This paradigm has altered with the advancements in the immunohistochemical analysis of BRCA1-Associated Protein 1 (BAP1) the lack of BAP1 expression shows the diagnosis of malignancy. DMPM is resistant to conventional chemotherapies. Therefore, the gold standard for the treatment of DMPM is the combination of cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC). The overexpression of the phosphatidylinositol 3-kinase (PI3K)\/AKT serine\/threonine kinase 1 (AKT)\/mammalian target of rapamycin (mTOR) signaling pathway drives the malignant phenotype of DMPM, thereby showing promising potential for the treatment of DMPM. The coordinated activities among multiple RTKs are directly involved in the biological processes of DMPM, suggesting that the combined inhibition of the PI3K and mTOR signaling pathways might be an effective measure. This treatment strategy can be easily implemented in clinical practice. However, the combined inhibition of ERBB1(HER1)\/ERBB2 (HER2) and ERBB3 (HER3) requires further investigations. Thus, based on these, the discovery of novel targeted therapies might be crucial to improving the prognosis of DMPM patients.<\/jats:p>","DOI":"10.3389\/fsurg.2022.1015884","type":"journal-article","created":{"date-parts":[[2023,1,6]],"date-time":"2023-01-06T06:20:11Z","timestamp":1672986011000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":16,"title":["Diffuse malignant peritoneal mesothelioma: A review"],"prefix":"10.3389","volume":"9","author":[{"given":"Luanbiao","family":"Sun","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chenguang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuohui","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,1,6]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1007\/s10552-009-9328-9","article-title":"Pleural and peritoneal mesotheliomas in SEER: age effects and temporal trends, 1973\u20132005","volume":"20","author":"Moolgavkar","year":"2009","journal-title":"Cancer Causes Control"},{"key":"B2","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1002\/path.1700120212","article-title":"A malignant tumor arising from the endothelium of peritoneum, and producing mucoid ascetic fluid","volume":"12","author":"Miller","year":"1908","journal-title":"J Pathol Bacteriol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"82","DOI":"10.4103\/0019-5278.146897","article-title":"Global mesothelioma epidemic: trend and features","volume":"18","author":"Bianchi","year":"2014","journal-title":"Indian J Occup Environ Med"},{"key":"B4","first-page":"32","article-title":"Peritoneal mesothelioma: a review","volume":"9","author":"Bridda","year":"2007","journal-title":"MedGenMed"},{"key":"B5","doi-asserted-by":"publisher","first-page":"e132","DOI":"10.1016\/j.jtho.2017.04.020","article-title":"Improving the accuracy of mesothelioma diagnosis in China","volume":"12","author":"Carbone","year":"2017","journal-title":"J Thorac Oncol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.ejso.2020.02.011","article-title":"Peritoneal mesothelioma: PSOGI\/EURACAN clinical practice guidelines for diagnosis, treatment and follow-up","volume":"47","author":"Kusamura","year":"2021","journal-title":"Eur J Surg Oncol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"177","DOI":"10.3816\/CLC.2003.n.031","article-title":"Molecular pathogenesis of malignant mesothelioma and its relationship to simian virus 40","volume":"5","author":"Gazdar","year":"2003","journal-title":"Clin Lung Cancer"},{"key":"B8","doi-asserted-by":"publisher","first-page":"1855","DOI":"10.1002\/cncr.25640","article-title":"A novel tumor-node-metastasis (TNM) staging system of diffuse malignant peritoneal mesothelioma using outcome analysis of a multi-institutional database*","volume":"117","author":"Yan","year":"2011","journal-title":"Cancer"},{"key":"B9","doi-asserted-by":"publisher","first-page":"S15","DOI":"10.1007\/s002800051093","article-title":"Successful management of microscopic residual disease in large bowel cancer","volume":"43","author":"Sugarbaker","year":"1999","journal-title":"Cancer Chemother Pharmacol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"814","DOI":"10.2214\/AJR.07.3628","article-title":"Peritoneal mesotheliomas: clinicopathologic features, CT findings, and differential diagnosis","volume":"191","author":"Park","year":"2008","journal-title":"AJR Am J Roentgenol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"1198","DOI":"10.1016\/j.ejso.2009.04.007","article-title":"Circulating CA125 and diffuse malignant peritoneal mesothelioma","volume":"35","author":"Baratti","year":"2009","journal-title":"Eur J Surg Oncol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1111\/jgh.13260","article-title":"CT Differentiation of diffuse malignant peritoneal mesothelioma and peritoneal carcinomatosis","volume":"31","author":"Liang","year":"2016","journal-title":"J Gastroenterol Hepatol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.21873\/anticanres.11205","article-title":"Computed tomographic features of malignant peritoneal mesothelioma","volume":"36","author":"Kato","year":"2016","journal-title":"Anticancer Res"},{"key":"B14","doi-asserted-by":"publisher","first-page":"1708","DOI":"10.1245\/s10434-014-4041-7","article-title":"Comparison of MRI and CT for predicting the peritoneal cancer Index (PCI) preoperatively in patients being considered for cytoreductive surgical procedures","volume":"22","author":"Low","year":"2015","journal-title":"Ann Surg Oncol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.ejso.2005.09.016","article-title":"Preoperative computed tomography and selection of patients with colorectal peritoneal carcinomatosis for cytoreductive surgery and hyperthermic intraperitoneal chemotherapy","volume":"32","author":"de Bree","year":"2006","journal-title":"Eur J Surg Oncol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1245\/s10434-008-0234-2","article-title":"Evaluation of preoperative computed tomography in estimating peritoneal cancer index in colorectal peritoneal carcinomatosis","volume":"16","author":"Koh","year":"2009","journal-title":"Ann Surg Oncol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.ejso.2019.02.030","article-title":"Peritoneal MRI in patients undergoing cytoreductive surgery and HIPEC: history, clinical applications, and implementation","volume":"47","author":"Low","year":"2021","journal-title":"Eur J Surg Oncol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11547-016-0682-x","article-title":"Diagnostic performance of computed tomography and magnetic resonance imaging for detecting peritoneal metastases: systematic review and meta-analysis","volume":"122","author":"Laghi","year":"2017","journal-title":"Radiol Med"},{"key":"B19","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1097\/MNM.0000000000000649","article-title":"The role of 18F-FDG-PET\/ceCT in peritoneal mesothelioma","volume":"38","author":"Dubreuil","year":"2017","journal-title":"Nucl Med Commun"},{"key":"B20","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/j.poly.2004.04.009","article-title":"Role of explorative laparoscopy to evaluate optimal candidates for cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with peritoneal mesothelioma","volume":"23","author":"Laterza","year":"2009","journal-title":"In Vivo"},{"key":"B21","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1245\/s10434-014-4136-1","article-title":"Port-site metastases is an independent prognostic factor in patients with peritoneal carcinomatosis","volume":"22","author":"Nunez","year":"2015","journal-title":"Ann Surg Oncol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1097\/PPO.0b013e3181a58e93","article-title":"Laparoscopy in the management of peritoneal carcinomatosis","volume":"15","author":"Garofalo","year":"2009","journal-title":"Cancer J"},{"key":"B23","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1002\/bjs.10723","article-title":"Multicentre study of laparoscopic or open assessment of the peritoneal cancer index (BIG-RENAPE)","volume":"105","author":"Passot","year":"2018","journal-title":"Br J Surg"},{"key":"B24","doi-asserted-by":"publisher","first-page":"397","DOI":"10.5858\/2008-132-397-AOITTD","article-title":"Application of immunohistochemistry to the diagnosis of malignant mesothelioma","volume":"132","author":"Marchevsky","year":"2008","journal-title":"Arch Pathol Lab Med"},{"key":"B25","doi-asserted-by":"publisher","first-page":"108","DOI":"10.5114\/PJP.2016.61445","article-title":"Comparison of SKIP expression in malignant pleural mesotheliomas with ki-67 proliferation index and prognostic parameters","volume":"67","author":"Turkcu","year":"2016","journal-title":"Pol J Pathol"},{"key":"B26","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.5858\/2005-129-1407-IDOEMA","article-title":"Immunohistochemical diagnosis of epithelioid mesothelioma: an update","volume":"129","author":"Ordonez","year":"2005","journal-title":"Arch Pathol Lab Med"},{"key":"B27","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1111\/j.1365-2559.2007.02743.x","article-title":"Claudin-4 in mesothelioma diagnosis","volume":"51","author":"Facchetti","year":"2007","journal-title":"Histopathology"},{"key":"B28","doi-asserted-by":"publisher","first-page":"241","DOI":"10.5858\/arpa.2010-0216-RA","article-title":"Epithelioid lesions of the serosa","volume":"136","author":"Anttila","year":"2012","journal-title":"Arch Pathol Lab Med"},{"key":"B29","doi-asserted-by":"publisher","first-page":"89","DOI":"10.5858\/arpa.2017-0124-RA","article-title":"Guidelines for pathologic diagnosis of malignant mesothelioma 2017 update of the consensus statement from the international mesothelioma interest group","volume":"142","author":"Husain","year":"2018","journal-title":"Arch Pathol Lab Med"},{"key":"B30","first-page":"14","article-title":"The immunohistochemical characterization of sarcomatoid malignant mesothelioma of the pleura","volume":"1","author":"Chirieac","year":"2011","journal-title":"Am J Cancer Res"},{"key":"B31","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1186\/s12872-019-1128-x","article-title":"Spatiotemporal variations in cardiovascular disease mortality in China from 1991 to 2009","volume":"19","author":"Ren","year":"2019","journal-title":"BMC Cardiovasc Disord"},{"key":"B32","doi-asserted-by":"publisher","first-page":"972","DOI":"10.4103\/ija.IJA_765_19","article-title":"Society of onco-anaesthesia and perioperative care consensus guidelines for perioperative management of patients for cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS-HIPEC)","volume":"63","author":"Solanki","year":"2019","journal-title":"Indian J Anaesth"},{"key":"B33","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1186\/s12957-022-02666-3","article-title":"Effect of hyperthermic intraperitoneal chemotherapy in combination with cytoreductive surgery on the prognosis of patients with colorectal cancer peritoneal metastasis: a systematic review and meta-analysis","volume":"20","author":"Li","year":"2022","journal-title":"World J Surg Oncol"},{"key":"B34","doi-asserted-by":"publisher","first-page":"6906","DOI":"10.3748\/wjg.v22.i30.6906","article-title":"Chinese Expert consensus on cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal malignancies","volume":"22","author":"Li","year":"2016","journal-title":"World J Gastroenterol"},{"key":"B35","doi-asserted-by":"publisher","first-page":"66S","DOI":"10.1378\/chest.113.1_Supplement.66S","article-title":"A review of chemotherapy trials for malignant mesothelioma","volume":"113","author":"Ryan","year":"1998","journal-title":"Chest"},{"key":"B36","doi-asserted-by":"publisher","first-page":"2636","DOI":"10.1200\/JCO.2003.11.136","article-title":"Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma","volume":"21","author":"Vogelzang","year":"2003","journal-title":"J Clin Oncol"},{"key":"B37","doi-asserted-by":"publisher","first-page":"40","DOI":"10.3816\/CLC.2005.n.020","article-title":"Open-label study of pemetrexed alone or in combination with cisplatin for the treatment of patients with peritoneal mesothelioma: outcomes of an expanded access program","volume":"7","author":"Janne","year":"2005","journal-title":"Clin Lung Cancer"},{"key":"B38","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/j.lungcan.2008.08.013","article-title":"Malignant peritoneal mesothelioma-results from the international expanded access program using pemetrexed alone or in combination with a platinum agent","volume":"64","author":"Carteni","year":"2009","journal-title":"Lung Cancer"},{"key":"B39","doi-asserted-by":"publisher","first-page":"3567","DOI":"10.1200\/JCO.2007.15.2868","article-title":"Pemetrexed plus gemcitabine as first-line chemotherapy for patients with peritoneal mesothelioma: final report of a phase II trial","volume":"26","author":"Simon","year":"2008","journal-title":"J Clin Oncol"},{"key":"B40","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1016\/S1055-3207(03)00045-0","article-title":"A review of peritoneal mesothelioma at the Washington cancer institute","volume":"12","author":"Sugarbaker","year":"2003","journal-title":"Surg Oncol Clin N Am"},{"key":"B41","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.1016\/j.ejso.2017.01.009","article-title":"Long-term regional chemotherapy for patients with epithelial malignant peritoneal mesothelioma results in improved survival","volume":"43","author":"Sugarbaker","year":"2017","journal-title":"Eur J Surg Oncol"},{"key":"B42","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1016\/j.jtcvs.2012.10.042","article-title":"Intraoperative hyperthermic chemotherapy perfusion for malignant pleural mesothelioma: an in vitro evaluation","volume":"145","author":"Cameron","year":"2013","journal-title":"J Thorac Cardiovasc Surg"},{"key":"B43","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1200\/JCO.1996.14.3.878","article-title":"Combined systemic chemoimmunotherapy in advanced diffuse malignant mesothelioma. Report of a phase I-II study of weekly cisplatin\/interferon alfa-2a","volume":"14","author":"Soulie","year":"1996","journal-title":"J Clin Oncol"},{"key":"B44","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1007\/s005950050200","article-title":"Successful immunochemotherapy for patients with malignant mesothelioma: report of two cases","volume":"28","author":"Tani","year":"1998","journal-title":"Surg Today"},{"key":"B45","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1016\/S1470-2045(13)70381-4","article-title":"Tremelimumab for patients with chemotherapy-resistant advanced malignant mesothelioma: an open-label, single-arm, phase 2 trial","volume":"14","author":"Calabro","year":"2013","journal-title":"Lancet Oncol"},{"key":"B46","doi-asserted-by":"publisher","first-page":"1168","DOI":"10.1164\/rccm.200501-057OC","article-title":"Immunotherapy of murine malignant mesothelioma using tumor lysate-pulsed dendritic cells","volume":"171","author":"Hegmans","year":"2005","journal-title":"Am J Respir Crit Care Med"},{"key":"B47","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1007\/s11912-020-0897-9","article-title":"Immune-Related adverse events (irAEs): diagnosis, management, and clinical pearls","volume":"22","author":"Darnell","year":"2020","journal-title":"Curr Oncol Rep"},{"key":"B48","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1111\/bju.15495","article-title":"The cancer multidisciplinary team meeting: in need of change? History, challenges and future perspectives","volume":"128","author":"Winters","year":"2021","journal-title":"BJU Int"},{"key":"B49","doi-asserted-by":"publisher","first-page":"5817","DOI":"10.3390\/ijms20225817","article-title":"Molecular signatures for combined targeted treatments in diffuse malignant peritoneal mesothelioma","volume":"20","author":"Belfiore","year":"2019","journal-title":"Int J Mol Sci"}],"container-title":["Frontiers in Surgery"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fsurg.2022.1015884\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,6]],"date-time":"2023-01-06T06:20:15Z","timestamp":1672986015000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fsurg.2022.1015884\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,6]]},"references-count":49,"alternative-id":["10.3389\/fsurg.2022.1015884"],"URL":"https:\/\/doi.org\/10.3389\/fsurg.2022.1015884","relation":{},"ISSN":["2296-875X"],"issn-type":[{"value":"2296-875X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,6]]},"article-number":"1015884"}}